December 8, 2016 / 5:00 PM / 8 months ago

BRIEF-Valeant announces phase 3 results for psoriasis treatment IDP-118

1 Min Read

Dec 8 (Reuters) - Valeant Pharmaceuticals International Inc :

* Valeant Pharmaceuticals announces phase 3 results for psoriasis treatment IDP-118

* Within phase 3 study of 215 adult subjects with moderate to severe psoriasis, IDP-118 showed statistical significance to vehicle

* Expects to have data from a second confirmatory pivotal phase 3 study in 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below